TPST.O Shares Plunge 50% Amid Acquisition News

Written by Emily J. Thompson, Senior Investment Analyst

Source: Investing.com

Updated: 19 Nov 25

Source: Investing.com

Shares of Tempest Therapeutics Inc. (TPST.O) declined sharply today, dropping 50% to $4.60 following the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. This significant price movement has pushed the stock near its 52-week low, as it crossed below its 5-day simple moving average, indicating increased bearish momentum.

The acquisition, while aimed at expanding Tempest's pipeline with the clinical-stage TPST-2003 program, is expected to lead to substantial shareholder dilution and a leadership change, with Factor co-founder Dr. Matt Angel set to replace current CEO Stephen Brady in early 2026. Market analysts are expressing concern over the implications of this deal on shareholder value, contributing to the stock's sharp decline.

As U.S. stocks showed mixed results today, the bearish signals surrounding TPST are particularly notable, reflecting broader market reactions to corporate announcements and performance indicators across various sectors.

TPST

$2.94+Infinity%1D

Analyst Views on TPST

About TPST

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

TPST.O Shares Plunge 50% Amid Acquisition News

Analyst Views on TPST

About TPST

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

ASML Declares €1.60 Quarterly Dividend and New Share Buyback Program

Chevron Appoints New Independent Director

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch